This article is more than 5 years old. Information may no longer be current.
VIDEO: ‘Patient’s voice’ must guide decisions about duration of adjuvant aromatase inhibitor therapy
SAN ANTONIO — Several abstracts at San Antonio Breast Cancer Symposium explored the question of the most appropriate duration of adjuvant aromatase inhibitor therapy for patients with breast cancer.
Results revealed modest DFS benefits with longer therapy but no significant OS improvement. Longer therapy also was associated with increased risk for osteoporotic fractures.
“In the future, we will see whether molecular assays or gene profiling may help us better select patients who will really get the biggest bang for their buck, who will derive the greatest benefit for extended endocrine therapy,” Andrew D. Seidman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center and a HemOnc Today Editorial Board member, told HemOnc Today. “We’re not quite there yet, and even when we do have those assays, hearing the patient’s voice and making these decisions will still remain a very important part of treatment.” – by Kristie L. Kahl
Disclosure: Seidman reports consultant and speakers roles with Roche/Genentech.